蒙凌华 - 中国科学院上海药物研究所 -

个人简介

蒙凌华，女，现任中国科学院上海药物研究所研究员、博士生导师。 1996 年6月毕业于华东师范大学生物系，同年进入中国科学院上海药物研究所攻读研究生，于 2001 年7月获得理学博士学位。 2001 年7月至 2006 年3月在美国国立卫生研究院国立癌症研究所分子药理研究实验室从事博士后研究。于2006年加入上海药物研究所历任副研究员，研究员。获奖及荣誉： 1. 2013年药明康德生命化学研究奖　　 2. 2011年明治生命科学奖-科学奖　　 3. 上海市第七届巾帼创新奖　　 4. 2010年赛诺菲·安万特-中国科学院上海生命科学研究院优秀青年人才奖，获奖人：蒙凌华　　 5. 2009年国家自然科学奖二等奖（排名第三）　　 6. 2008年中国药理学会施维雅青年药理学工作者

研究领域

主要从事靶向PI3K-mTOR通路抑制剂的研究和开发以及相关信号通路研究。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Wang X, Ding J, Meng LH* PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. Acta Pharmacol Sin. 2015;36:1170-6. Wei M, Wang X, Song Z, Jiao M, Ding J, Meng LH*, Ao Zhang. Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond. Medicinal Research Reviews 2015; 35(4):720-52 Wang X, Zhang X, Li BS, Zhai X, Yang Z, Ding LX, Wang H, Liang C, Zhu W, Ding J*, Meng LH*. Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia. Oncotarget. 2014；5:10732-44. Chen SM, Guo CL, Shi JJ, Chen Y, Shen YY, Su Y, Ding J, Meng LH*. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer. Intl J Cancer 2014; 135:2462-74. Liu J， Gao G，Zhang X，Cao S，Guo C，Wang X，Tong L，Ding J， Duan W and Meng LH*. DW09849, a selective PI3K inhibitor, Prevents PI3K signaling and preferentially inhibits proliferation of p110α (H1047R) mutated cells. J Pharmacol Exp Ther. 2014; 348:432-41. Li X, Tong L-J, Ding J*, Meng LH*. Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer. Cancer Lett. 2014；42:159-66. Zhao Y, Zhang X, Chen Y, Lu S, Peng Y, Wang X, Guo C, Zhou A, Zhang J, Luo Y, Cheng Q, Ding J, Meng LH*, Zhang J*. Crystal structures of PI3Kα complexed with PI103 and Its derivatives: new directions for inhibitors design. ACS Medicinal Chemistry Letters. 2013; 5:138-42. Wang X, Li J-p, Yang Y, Ding J*, Meng L-H*: A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth. Acta pharmacologica Sinica. 2013; 34:1201-7. Chen G, Chen1 SM, Wang X, Ding XF, Ding J* and Meng LH*. Inhibition of chemokine (C-X-C motif) ligand 12/chemokine (C-X-C motif) receptor 4 axis （CXCL12/CXCR4）-mediated cell migration by targeting mammalian target of rapamycin （mTOR） pathway in human gastric carcinoma cells. J Biol Chem 2012；287:12132-41 Chen SM, Liu JL, Wang X, Liang C, Ding J* and Meng LH*. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of tumor. Biochem Pharmacol 2012；83:1183-94 Meng L* and Ding J*. Identification of Candidate Biomarkers Predicting Response to Rapalogs Therapy in Human Cancer. Rapamycin: Effectiveness, Safety and Drug Interactions. Nova Publishers. ISBN-10: 1619426420; 2012 ;53-67. Yao Y, Liu J, Xi J, Miu K, Liu G, Wang S, Meng LH,* and Yao ZJ*. Total Synthesis of 7-Ethyl-10-hydroxycamptothecin (SN38) and its Application to the Development of C18-Functionalized Camptothecin Derivatives . Chem. Eur. J. 2011, 17, 10462 -10469